2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

ased software and tools, such as R for all analyses.
Releasing scripts that formally document all stages of the
genomic and proteomic analyses with raw data when submitting
for publication can provide an additional quality
assurance of the analyses at the manuscript-review stage. 30
Although disclosure of the analysis scripts and subsequent
review cannot eliminate all mistakes from complex data
analyses, they allow others to reproduce the results and can
Authors’ Disclosures of Potential Conflicts of Interest
Author
Employment or
Leadership
Positions
Consultant or
Advisory Role
Elana J. Fertig*
Robbert Slebos*
Christine H. Chung Boehringer
Ingelheim;
Bristol-Myers
Squibb
*No relevant relationships to disclose.
1. McPherson JD, Marra M, Hillier L, et al. A physical map of the human
genome. Nature. 2001;409:934-941.
2. Venter JC, Adams MD, Myers EW, et al. The sequence of the human
genome. Science. 2001;291:1304-1351.
3. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of
head and neck squamous cell carcinoma. Science. 2011;333:1157-1160.
4. Agrawal N, Frederick MJ, Pickering CR, et al. Exome sequencing of head
and neck squamous cell carcinoma reveals inactivating mutations in
NOTCH1. Science. 2011;333:1154-1157.
5. Brown PO, Botstein D. Exploring the new world of the genome with DNA
microarrays. Nat Genet. 1999;21:33-37.
6. Chung CH, Levy S, Chaurand P, Carbone DP. Genomics and proteomics:
emerging technologies in clinical cancer research. Crit Rev Oncol Hematol.
2007;61:1-25.
7. Ledford H. The death of microarrays? Nature. 2008;455:847.
8. Metzker ML. Sequencing technologies—the next generation. Nat Rev
Genet. 2010;11:31-46.
9. Trapnell C, Salzberg SL. How to map billions of short reads onto
genomes. Nat Biotechnol. 2009;27:455-457.
10. Yates JR, Ruse CI, Nakorchevsky A. Proteomics by mass spectrometry:
approaches, advances, and applications. Annu Rev Biomed Eng. 2009;11:49-
79.
11. Leek JT, Scharpf RB, Bravo HC, et al. Tackling the widespread and
critical impact of batch effects in high-throughput data. Nat Rev Genet.
2011;11:733-739.
12. Eisen MB, Spellman PT, Brown PO, et al. Cluster analysis and display
of genome-wide expression patterns. Proc Natl Acad Sci USA.1998;95:
14863-14868.
13. Ringner M. What is principal component analysis? Nat Biotechnol.
2008;26:303-304.
14. Lee DD, Seung HS. Learning the parts of objects by non-negative
matrix factorization. Nature. 1999;401:788-791.
15. Ochs MF, Stoyanova RS, Arias-Mendoza F, et al. A new method for
spectral decomposition using a bilinear Bayesian approach. J Magn Reson.
1999;137:161-176.
16. Gaujoux R, Seoighe C. A flexible R package for nonnegative matrix
factorization. BMC Bioinformatics. 2010;11:367.
382
further facilitate validation of any genomic signatures before
clinical application.
Acknowledgment
The authors appreciate the assistance of Michael F. Ochs,
Sarah Wheelan, and Luigi Marchioni in writing this manuscript.
Stock
Ownership Honoraria
REFERENCES
Research
Funding
AstraZeneca;
Bayer; Lilly
FERTIG, SLEBOS, AND CHUNG
Expert
Testimony
Other
Remuneration
17. Fertig EJ, Ding J, Favorov AV, et al. CoGAPS: an R/C�� package to
identify patterns and biological process activity in transcriptomic data.
Bioinformatics. 2010;26:2792-2793.
18. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays
applied to the ionizing radiation response. Proc Natl Acad Sci U S A.
2001;98:5116-5121.
19. Smyth GK. Bioinformatics and Computational Biology Solutions Using
R and Bioconductor (ed XIX), Springer, 2005:397-420.
20. Winchester L, Yau C, Ragoussis J. Comparing CNV detection methods
for SNP arrays. Brief Funct Genomic Proteomic. 2009;8:353-366.
21. Noble WS. How does multiple testing correction work? Nat Biotechnol.
2009;27:1135-1137.
22. Ressom HW, Varghese RS, Zhang Z, et al. Classification algorithms for
phenotype prediction in genomics and proteomics. Front Biosci. 2008;13:691-
708.
23. Chung CH, Parker JS, Karaca G, et al. Molecular classification of head
and neck squamous cell carcinomas using patterns of gene expression. Cancer
Cell. 2004;5:489-500.
24. Chung CH, Parker JS, Ely K, et al. Gene expression profiles identify
epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB
signaling as characteristics of a high-risk head and neck squamous cell
carcinoma. Cancer Res. 2006;66:8210-8218.
25. Pramana J, Van den Brekel MW, van Velthuysen ML, et al. Gene
expression profiling to predict outcome after chemoradiation in head and neck
cancer. Int J Radiat Oncol Biol Phys. 2007;69:1544-1552.
26. Schaaij-Visser TB, Graveland AP, Gauci S, et al. Differential proteomics
identifies protein biomarkers that predict local relapse of head and neck
squamous cell carcinomas. Clin Cancer Res. 2009;15:7666-7675.
27. Matta A, Ralhan R, DeSouza LV, et al. Mass spectrometry-based
clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery.
Mass Spectrom Rev. 2010;29:945-961.
28. Halvey PJ, Zhang B, Coffey RJ, et al. Proteomic consequences of a
single gene mutation in a colorectal cancer model. J Proteome Res. 2012;11:
1184-1195.
29. Ioannidis JP, Allison DB, Ball CA, et al. Repeatability of published
microarray gene expression analyses. Nat Genet. 2009;41:149-155.
30. Baggerly K. Disclose all data in publications. Nature. 2010; 467:401.